Back to Search
MARK PEGRAM, M.D.
M.D.
Medical Oncology Physician
NPI: 1356361554Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
PMID 18777951·Clin Breast Cancer·2008
6-review
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.
PMID 16876287·Adv Drug Deliv Rev·2006
6-review
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
PMID 15150304·J Natl Cancer Inst·2004
3-trial
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
PMID 15150302·J Natl Cancer Inst·2004
7-preclinical
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
PMID 12138395·Semin Oncol·2002
6-review
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
PMID 11970740·Clin Breast Cancer·2001
6-review
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
PMID 11049052·Semin Oncol·2000
8-other
Trastuzumab and chemotherapeutics: drug interactions and synergies.
PMID 11236023·Semin Oncol·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 900 BLAKE WILBUR DR, 1ST FLOOR
PALO ALTO, CA 94304 - Phone
- (650) 498-6004
Quick Facts
- NPI
- 1356361554
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile